文献速递前列腺癌

转移性去势抵抗性前列腺癌中PARP抑制剂治疗效应的异质性:一项动态交互式系统评价与Meta分析

Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol · 2025-01-23

该动态交互式系统评价与Meta分析纳入13项试验共4278例转移性去势抵抗性前列腺癌患者,评估PARP抑制剂单药或联合雄激素受体通路抑制剂在不同同源重组修复基因突变患者中的疗效差异。结果显示BRCA突变患者获益最大,PALB2或CDK12突变有较强获益信号,ATM或CHEK2突变未见获益。

要点

  • BRCA突变患者接受PARP抑制剂联合ARPI的影像学无进展生存期显著获益(HR 0.28,95%CI 0.13-0.62),总生存期亦获益(HR 0.47,95%CI 0.31-0.71)。
  • PALB2或CDK12突变患者显示较强获益信号,但PALB2的影像学无进展生存期未达统计学显著(HR 0.53,95%CI 0.21-1.32)。
  • ATM或CHEK2突变患者未见获益,影像学无进展生存期HR分别为0.93(95%CI 0.57-1.53)和0.92(95%CI 0.53-1.61)。

核心结论

  • 证据提示BRCA突变患者PARP抑制剂获益最大,PALB2或CDK12突变有较强获益信号,ATM或CHEK2突变未见获益。

研究设计与样本

  • 动态交互式系统评价与Meta分析,采用Living Interactive Evidence synthesis框架,纳入13项试验共4278例患者。
  • 纳入评估PARP抑制剂单药用于经治mCRPC或联合ARPI用于初治患者的临床试验。
  • 按HRR状态、BRCA状态及每个基因进行预设亚组的随机效应Meta分析。

主要发现

  • 经治mCRPC接受PARP抑制剂单药时,每100人月的肿瘤缓解率:BRCA2突变患者PSA50%为3.3、ORR为3.3;BRCA1突变患者PSA50%为1.2、ORR为2.0;PALB2突变患者PSA50%为3.3、ORR为1.4;ATM突变患者PSA50%为0.4、ORR为0.3;CDK12突变患者PSA50%为0.2、ORR为0.2;CHEK2突变患者PSA50%为1.0、ORR为0.7。
  • 接受PARP抑制剂联合ARPI的患者中,BRCA突变者影像学无进展生存期显著获益(HR 0.28,95%CI 0.13-0.62),CDK12突变者亦显著获益(HR 0.58,95%CI 0.35-0.95)。
  • 接受PARP抑制剂联合ARPI的患者中,PALB2突变者影像学无进展生存期未达统计学显著(HR 0.53,95%CI 0.21-1.32),ATM突变者未达统计学显著(HR 0.93,95%CI 0.57-1.53),CHEK2突变者未达统计学显著(HR 0.92,95%CI 0.53-1.61)。
  • 校正交叉和后续治疗后,BRCA突变患者总生存期获益(HR 0.47,95%CI 0.31-0.71),PALB2突变者未达统计学显著(HR 0.33,95%CI 0.10-1.16),ATM突变者未达统计学显著(HR 0.97,95%CI 0.57-1.67),CDK12突变者未达统计学显著(HR 0.80,95%CI 0.36-1.78),CHEK2突变者未达统计学显著(HR 0.81,95%CI 0.37-1.75)。

临床怎么用

  • 该动态Meta分析通过交互式网络平台提供PARP抑制剂治疗与mCRPC特定基因突变相关的疗效信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Selection of patients harboring mutations in homologous recombination repair (HRR) genes for treatment with a PARP inhibitor (PARPi) is challenging in metastatic castration-resistant prostate cancer (mCRPC). To gain further insight, we quantitatively assessed the differential efficacy of PARPi therapy among patients with mCRPC and different HRR gene mutations. METHODS: This living meta-analysis (LMA) was conducted using the Living Interactive Evidence synthesis framework. We included clinical trials assessing PARPi as monotherapy in pretreated mCRPC or in combination with an androgen receptor pathway inhibitor (ARPI) in treatment-naïve patients. Random-effects meta-analyses were performed for a priori subgroups stratified by HRR status, BRCA status, and each gene. KEY FINDINGS AND LIMITATIONS: This first report for our LMA includes 13 trials (4278 patients). Among patients with pretreated mCRPC receiving PARPi monotherapy, the tumor response rate per 100 person-months was numerically higher for patients with BRCA2 (50% prostate-specific antigen response [PSA50%] 3.3; objective response rate [ORR] 3.3), BRCA1 (PSA50% 1.2; ORR 2.0), or PALB2 (PSA50% 3.3; ORR 1.4) alterations than for patients with ATM (PSA50% 0.4; ORR 0.3), CDK12 (PSA50% 0.2; ORR 0.2), or CHEK2 (PSA50% 1.0; ORR 0.7) alterations. Among patients receiving PARPi + ARPI, a significant radiographic progression-free survival benefit was observed in those with BRCA (hazard ratio [HR] 0.28, 95% confidence interval [CI] 0.13-0.62) or CDK12 (HR 0.58, 95% CI 0.35-0.95) alterations, but not in patients with PALB2 (HR 0.53, 95% CI 0.21-1.32), ATM (HR 0.93, 95% CI 0.57-1.53), or CHEK2 (HR 0.92, 95% CI 0.53-1.61) alterations. An overall survival benefit was observed for patients with BRCA alterations (HR 0.47, 95% CI 0.31-0.71) after adjustment for crossover and subsequent therapy, but not for patients with PALB2 (HR 0.33, 95% CI 0.10-1.16), ATM (HR 0.97, 95% CI 0.57-1.67), CDK12 (HR 0.80, 95% CI 0.36-1.78), or CHEK2 (HR 0.81, 95% CI 0.37-1.75) alterations. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our LMA delivers information on the effect of PARPi therapy in relation to specific gene alterations in mCRPC via an interactive web platform. The evidence suggests the greatest PARPi benefit in patients with BRCA alterations, a strong signal of benefit in patients with PALB2 or CDK12 alterations, and no benefit in patients with ATM or CHEK2 alterations.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Naqvi SAA, Riaz IB, Bibi A, et al. Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis. Eur Urol. 2025. PMID: 39848867. doi:10.1016/j.eururo.2024.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。